N-Nitroso Sitagliptin D4 99%
| Price | Get Latest Price | ||
| Packge | 1and gm | 100mg | 500mg |
- Min. Order:100mg
- Time:2025-07-07
Product Details
- Product NameN-Nitroso Sitagliptin D4
- MW0
Company Profile Introduction
Accelerating Pharmaceutical innovation through our molecular expertise
At Aquigen BioSciences, we understand your search for a perfect product that fits your research requirements. We provides various services to support pharmaceutical research and development. We offer a wide range of Impurity Standards to help researchers test drug purity. Our services contain Deuterated Labelled Compounds which are useful for metabolism studies. Moreover, we supply Peptide Impurity Standards for peptide drug development. Aquigen undertakes custom synthesis projects to manufacture APIs, drug intermediates, and other molecules as required by customers. We have capabilities in API Intermediate and Custom Synthesis to optimize synthetic routes for new drug candidates. In addition, analytical services such as impurity isolation and characterization are available.
Supplier other products
Recommended supplier
-
VIP3年
- GLP Pharma Standards
- 67856-68-2 N- nitroso bis (2- chloro ethyl amine)/N-Nitroso Cyclophosphamide USP Related Compound A NLT 95%
- Inquiry
- 2026-01-27
-
VIP0年
- GLP Pharma Standards
- 67856-68-2 N- nitroso bis (2- chloro ethyl amine)/N-Nitroso Cyclophosphamide USP Related Compound A NLT 95%
- Inquiry
- 2026-01-27
-
VIP2年
- Clickchem Research LLP
- 73486-81-4 N-NITROSO HEEP/N-NITROSO QUETIAPINE 90 % Above
- Inquiry
- 2025-06-18
-
VIP0年
- Clickchem Research LLP
- 73486-81-4 N-NITROSO HEEP/N-NITROSO QUETIAPINE 90 % Above
- Inquiry
- 2025-06-18
-
VIP3年
- GLP Pharma Standards
- 2763780-10-3 N-nitroso bupropian/Bupropion Nitroso Impurity NLT 95%
- Inquiry
- 2026-01-27
-
VIP0年
- GLP Pharma Standards
- 2763780-10-3 N-nitroso bupropian/Bupropion Nitroso Impurity NLT 95%
- Inquiry
- 2026-01-27
- Since:2018-04-26
- Address: 281/1 Plot, 41, Hinjewadi - Pirangut Road, Kasar Amboli, Pirangut, Maharashtra 412108 India
INQUIRY
